FIB-4 is not one size fits all: real-life accuracy and misclassification in a multicentre italian hepatology cohort

Imagine your body is a bustling city, and your liver is the main recycling plant, working hard to filter out toxins and keep everything running smoothly. Sometimes, because of too much sugar, fat, or a sedentary lifestyle, this plant gets clogged with grease. This condition, now called metabolic dysfunction–associated steatotic liver disease (MASLD), is like a slow-motion traffic jam in the recycling center. If left unchecked, the plant can get scarred and stiff, a process called fibrosis, which eventually stops it from working altogether. The big question for doctors is: how do we spot the clogged plants before they break down?

To solve this, doctors use a "two-step" security check. First, they run a quick, free, and easy math test called FIB-4. It's like a metal detector at the airport: it uses your age and some blood numbers to guess if you might have a problem. If the score is low, you're good to go. If it's high, you get sent to the second step: a special machine called a Fibroscan that actually pokes your liver to measure how stiff it is. The big idea behind this paper is that while this metal detector is supposed to be a reliable guide, it might not be perfect for everyone. The researchers wanted to see if this "one-size-fits-all" tool works equally well for a teenager, a grandparent, a person with diabetes, or someone who is very heavy, or if it needs to be tuned differently for different people.

In a large study across nine Italian hospitals, scientists looked at 2,638 real-life patients who had been diagnosed with MASLD. They wanted to see how well the FIB-4 math test matched up with the actual "poking" test (the Fibroscan) that measures liver stiffness. Think of it like testing a weather app: does the app's prediction of rain actually match what happens outside?

The results showed that the FIB-4 test is a bit of a mixed bag. In the group studied, 21.9% of patients actually had stiff livers (measured as LSM ≥ 8 kPa), but the FIB-4 test did not identify all of them correctly. Specifically, among the people the test said were "safe" (low FIB-4 score), 13.2% actually had stiff livers. These are "false negatives"—people who were told they were fine when they actually needed help. On the flip side, 58.7% of the people the test flagged as "at risk" (high FIB-4 score) actually had soft, healthy livers. These are "false positives"—people who got sent for the expensive second test even though they didn't need it.

The study found that the test's accuracy wasn't the same for everyone; it depended heavily on who was being tested. The test worked best for older people (65 and up), where it was quite good at spotting the problem. However, for younger people (under 45), the test was much less reliable, acting more like a coin flip. Similarly, the test struggled with people who had obesity or severe fat in their liver. In fact, the test was so much less accurate for people with obesity that the researchers suggest the "safe" cutoff number needs to be lower for them to avoid missing the diagnosis.

The paper concludes that FIB-4 is a helpful tool, but it is not a perfect crystal ball. It showed only "moderate" performance overall, with a success rate (sensitivity) of 59% and a rule-out accuracy of 87%. The authors suggest that because the test misses so many people with diabetes, high blood pressure, or obesity, doctors shouldn't rely on it blindly. Instead, for patients with these extra risk factors, it might be better to consider direct fibrosis assessment to make sure no one gets missed. The key takeaway is that in the world of liver health, one rule doesn't fit all; the thresholds need to be adjusted based on the patient's age and body type to get the right answer.